LifeCell snared in $1.7B buyout deal

Kinetic Concepts has inked a deal to buy LifeCell for $1.7 billion, a cash transaction that applies an 18 percent premium to the maker of tissue-based products. In the deal, LifeCell becomes a biosurgery division of Kinetic Concepts. LifeCell will remain in Branchburg, NJ.

"This combination allows us to accelerate our strategy to increase Kinetic's presence in the operating room and will leverage our broad global market reach to drive future growth of LifeCell's products," said Kinetic CEO Catherine Burzik in a statement.

- see the release
- read the AP report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.